Compare FCEL & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCEL | BBOT |
|---|---|---|
| Founded | 1969 | 2016 |
| Country | United States | United States |
| Employees | 629 | 106 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 725.8M | 705.7M |
| IPO Year | N/A | N/A |
| Metric | FCEL | BBOT |
|---|---|---|
| Price | $25.00 | $8.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $8.31 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 10.7M | 362.8K |
| Earning Date | 06-05-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.77 | N/A |
| Revenue Next Year | $42.46 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.78 | $7.60 |
| 52 Week High | $26.90 | $14.87 |
| Indicator | FCEL | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 71.51 | 49.24 |
| Support Level | $6.55 | $8.08 |
| Resistance Level | N/A | $9.73 |
| Average True Range (ATR) | 3.16 | 0.57 |
| MACD | 0.76 | 0.11 |
| Stochastic Oscillator | 85.07 | 59.04 |
FuelCell Energy Inc is a clean energy technology company engaged in the development, design, production, and servicing of high temperature fuel cells for clean electric power generation. The Company provides proprietary molten carbonate fuel cell systems that generate electricity electrochemically with ultra low emissions and high efficiency, and operates as a solutions provider managing the design, manufacturing, installation, and maintenance of its systems under long term power purchase, service, and engineering procurement agreements. The Company serves utilities, data centers, and commercial and industrial customers, and operates in the United States, South Korea, Europe, and Canada, with maximum revenue generated from the United States.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.